Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-04-26
2005-04-26
Celsa, Bennett (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S832000, C530S385000, C530S829000
Reexamination Certificate
active
06884773
ABSTRACT:
Diseases which can be ameliorated by delivery of NO to tissues affected by the disease can be treated by administration of nitrosyl-heme-containing donors of NO, including nitrosylhemoglobin. Nitrosylhemoglobin can be made by the reaction of NO with hemoglobin under certain conditions in which the NO:hemoglobin ratio is critical, and is converted to SNO-Hb under physiological conditions.
REFERENCES:
patent: 4900719 (1990-02-01), Means et al.
patent: 5380758 (1995-01-01), Stamler et al.
patent: 5385937 (1995-01-01), Stamler et al.
patent: 5395314 (1995-03-01), Klatz et al.
patent: 5405919 (1995-04-01), Keefer et al.
patent: 5427797 (1995-06-01), Frostell et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5480866 (1996-01-01), Bonaventura et al.
patent: 5574068 (1996-11-01), Stamler et al.
patent: 5583101 (1996-12-01), Stamler et al.
patent: 5593876 (1997-01-01), Stamler et al.
patent: 5863890 (1999-01-01), Stamler et al.
patent: 6087479 (2000-07-01), Stamler et al.
patent: 6255277 (2001-07-01), Stamler et al.
patent: 6291424 (2001-09-01), Stamler et al.
patent: 20020052314 (2002-05-01), Stamler et al.
patent: 20030007967 (2003-01-01), Stamler et al.
patent: 20030022267 (2003-01-01), Stamler et al.
patent: WO 9309806 (1993-05-01), None
patent: WO 9312068 (1993-06-01), None
patent: WO 9422306 (1994-10-01), None
patent: WO 9422482 (1994-10-01), None
patent: WO 9422499 (1994-10-01), None
patent: WO 9507691 (1995-03-01), None
patent: WO 9603139 (1996-02-01), None
patent: WO 9615797 (1996-05-01), None
patent: WO 9616645 (1996-06-01), None
patent: WO 9617604 (1996-06-01), None
patent: WO 9630006 (1996-10-01), None
patent: WO 9718000 (1997-05-01), None
patent: WO 9737644 (1997-10-01), None
U.S. Appl. No. 08/123,331, filed Sep. 17, 1993, now abandoned.
U.S. Appl. No. 08/438,418, filed May 10, 1995, now US 6,255,277.
U.S. Appl. No. 08/460,465, filed Jun. 2, 1995, now US 6,087,479.
U.S. Appl. No. 09/433,550, filed Nov. 4, 1999, now US 6,174,539.
U.S. Appl. No. 09/621,610, filed Jul. 21, 2000, now US 6,471,978.
U.S. Appl. No. 09/661,190, filed Sep. 13, 2000, now US 6,352,709.
U.S. Appl. No. 07/791,668, filed Nov. 14, 1991, now abandoned.
U.S. Appl. No. 08/198,854, filed Feb. 17, 1997, now abandoned.
U.S. Appl. No. 08/287,830, filed Aug. 9, 1994, now US 5,593,876.
U.S. Appl. No. 08/437,868, filed May 9, 1995, now abandoned.
U.S. Appl. No. 08/907,217, filed Aug. 6, 1997, now US 5,863,890.
U.S. Appl. No. 09/835,038, filed Apr. 16, 2001, published as 20020052314 (cited on PTO form 1449). The status and currently pending claims of this appliction are not known to Applicant.
U.S. Appl. No. 10/216,865, filed Aug. 13, 2002, published as 20030007967 (cited on PTO form 1449). The status and currently pending claims of this application are not known to Applicant.
U.S. Appl. No. 08/281,427, filed Jul. 27, 1994, which is the priority application for WO 96/03139. Status unknown to Applicant.
U.S. Appl. No. 08/043,653, filed Apr. 6, 1993, now US 5,427,797.
U.S. Appl. No. 10/066,320, filed Jan. 31, 2002, published as 20030022267 (cited on PTO form 1449). A copy of the claims currently pending is attached.
U.S. Appl. No. 10/280,085, filed Oct. 25, 2002. A copy of the claims currently pending is attached.
Search results from Derwent Word Patent Index: Stamler patent applications as of Mar. 12, 2001 (26 pages).
Wade, Ruth S. and Castro, C.E., “Redox Reactivity of Iron(III) Porphyrins and Heme Proteins with Nitric Oxide: Nitrosyl Transfer to Carbon, Oxygen, Nitrogen and Sulfur,”Chem. Res. Toxicol., 3(4):289-291 (1990).
Addison, Anthony W. and Stephanos, Joseph j., “Nitrosyliron (III) Hemoglobin: Autoreduction and Spectroscopy,”Biochemistry 25(14):4104-4113 (1986).
Perutz, Max F., et al., “Influence of Globin Structures on the State of the Heme: Ferrous Low Spin Derivatives,”Biochemistry, 15(2):378-387 (1976).
John, Maliyakal E. and Waterman, Michael R., “Structural Basis for the Conformational States of Nitrosyl Hemoglobins M Saskatoon and M Milwaukee,”The Journal of Biological Chemistry, 255(10):4501-4506 (1980).
Trittelvitz, Eberhard and Gersonde, Klaus, “Electron-Spiin Resonance of Nitrosyl Haemoglobins: Normal α and β Chains and Mutants Hb M Iwate and Hb Zürich,”Eur. J. Biochem., 51:33-42 (1975).
Lancaster, Jack R., Jr., “Simulation of the Diffusion and Reaction of Endogenously Produced Nitric Oxide,”Proc. Natl. Acad. Sci. USA, 91:8137-8141 (1994).
Butler, Anthony R. et al., “NO, Nitrosonium Ions, Nitroxide Ions, Nitrosothiols and Iron-Nitrosyls in Biology: A Chemist's Perspective,”TiPS, 16:18-22 (1995).
Sharma, Vijay S. and Ranney, Helen M., “The Dissociation of NO from Nitrosylhemoglobin,”The Journal of Biological Chemistry, 253(18):6467-6472 (1978).
Moore, Edwin G. and Gibson, Quentin H., “Cooperativity in the Dissociation of Nitric Oxide from Hemoglobin,”The Journal of Biological Chemistry, 251(9):2788-2794 (1976).
Khartitonov, V.G., et al., “Interactions of Nitric Oxide with Heme Proteins Using UV-VIS Spectroscopy,”Methods in Nitric Oxide Research, pp. 39-45, Edited by Martin Feelisch and Jonathan S. Stamler, John Wiley & Sons Ltd. (1996).
Taketa, Fumito, et al., “Chain Nonequivalence in Binding of Nitric Oxide to Hemoglobin,”The Journal of Biological Chemistry, 253(15):5448-5451 (1978).
Henry, Y. and Cassoly, R., “Chain Non-Equivalence in Nitric Oxide Binding to Hemoglobin,”Biochemical and Biophysical Research Communications, 51(3):659-665 (1973).
Wennmalm, ÅA., et al., “Dependence of the Metabolism of Nitric Oxide (NO) in Healthy Human Whole Blood on the Oxygenation of Its Red Cell Haemoglobin,”Br. Journal Pharmacol., 106:507-508 (1992).
Hille, Russ, et al., “Spectral Transitions of Nitrosyl Hemes During Ligand Binding to Hemoglobin,”The Journal of Biological Chemistry, 254(23):12110-12120 (1979).
Cassoly, R. and Gibson, Q.H., “Conformation, Co-Operativity and Ligand Binding in Human Hemoglobin,”J. Mol. Biol., 91:301-313 (1975).
Cantilena, Louis R., Jr., et al., “Nitric Oxide Hemoglobin in Patients Receiving Nitroglycerin as Detected by Electron Paramagnetic Resonance Spectroscopy,”J. Lab. Clin. Med., 120(6):902-907 (1992).
Salhany, J.M, et al., “Correlations Between Quaternary Structure and Ligand Dissociation Kinetics for Fully Liganded Hemoglobin,”Biochemistry, 14(10):2180-2190 (1975).
Kruszyna, Harriet, et al., “Red Blood Cells Generate Nitric Oxide From Directly Acting, Nitrogenous Vasodilators,”Toxicology and Applied Pharmacology, 91:429-438 (1987).
Stamler, Jonathan S. et al., “S-Nitrosylaton of Proteins with Nitric Oxide: Synthesis and Characterization of Biologically Active Compounds,”Proc. Natl. Acad. Sci. USA, 89:444-448 (1992).
Langford, E.J. et al., “Inhibition of Platelet Activity by S-Nitrosoglutathione During Coronary Angioplasty,”The Lancet, 344:1458-1460 (1994).
Simon, Daniel I. et al., “Polynitrosylated Proteins: Characterization, Bioactivity, and Functional Consequences,”Proc. Natl. Acad. Sci. USA, 93:4736-4741 (1996).
Doyle, Michael P. et al., “Structural Effects in Alkyl Nitrite Oxidation of Human Hemoglobin,”Journal of Biological Chemistry. 259(1):80-87 (1984).
Shah, N.S. et al., “Efficiacy of Inhaled Nitric Oxide in a Porcine MOdel of Adult Respiratory Distress Syndrome,”Archives of Surgery, 129(2):158-164 (1994).
Kukovetz, W.R. et al., “Cellular Mechanism of Action of Therapeutic Nitric Oxide Donors,”European Heart Journal, 12(Suppl. E) :16-24 (1991).
Greenburg, A.G. and Kim, H.W., “Nitrosyl Hemoglobin Formation In Vivo After Intravenous Administration of a Hemoglobin-Based Oxygen Carrier in Endotoxemic Rats,”Artif. Cells, Blood Substitutes, Immobilization Biotechnol., 23(3):271-276 (1995).
Clancy, Robert M. et al., “Use of Thionitrobenzoic Acid to Characterize the Stability of Nitric Ox
Gow Andrew J.
Stamler Jonathan S.
Celsa Bennett
Duke University
Hamilton Brook Smith & Reynolds P.C.
LandOfFree
Modified hemoglobins, including nitrosylhemoglobins, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified hemoglobins, including nitrosylhemoglobins, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified hemoglobins, including nitrosylhemoglobins, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3403669